A new study details how a nasal spray formulated by investigators from Brigham and Women's Hospital may work to protect ...
Study explores the potential to repurpose neuroactive drugs, originally approved for neurological disorders, for the ...
Hudson Therapeutics Announces Shaperon’s Entry $9.58 Billion Global Alopecia Areata Treatment Market
Hudson Therapeutics, a leading innovator in therapeutic solutions and a US subsidiary of Shaperon, announced Shaperon’s entry ...
Scientists have uncovered critical differences between how innate-like T cells mature in humans and mice. Early in life, most innate-like T cells in the human thymus aren't able to use all of their ...
Men and women don’t experience pain the same way. Give someone an electric shock; bind a tourniquet tighter and tighter ...
Dr. Jeremy Farrar, WHO’s Chief Scientist, emphasized the importance of strengthening country-led R&D and integrating clinical ...
Westside Current on MSN6d
Rakuten Medical Presented Research Results of Preclinical Studies for PD-L1-Targeted Photoimmunotherapy at The 83rd Annual Meeting of The Japanese Cancer Association 2024Presentation of in vitro studies of RM-0256, a novel anti-PD-L1 antibody conjugated to IR700, which comprises a dual mode of photoimmunotherapy: depletion of PD-L1 expressing tumor cells and depletion ...
GlobalData on MSN6d
Tectonic Therapeutic reports findings from Phase Ia trial of TX45The trial results indicated minimal adverse events and no evidence of immune-mediated clearance following TX45 treatment.
Another contender has emerged in the race to develop oral GLP-1 drugs for weight loss. Biolexis Therapeutics’ small molecule ...
Before 1993, women were rarely included in clinical trials. Today, the medical field still doesn’t know how well many drugs ...
Palvelussamme on juuri nyt häiriö, yritäthän myöhemmin uudelleen. Pahoittelemme aiheutunutta haittaa.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback